Trends in clinical success rates

Smietana, Katarzyna, Siatkowski, Marcin, Møller, Martin·2016·Nature Reviews Drug Discovery
DOI 10.1038/nrd.2016.85

Cited by (278)

Items 201–278 of 278

  1. Preexisting evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review
    Giacomo Bregni, Elena Trevisi, Rita Saúde Conde · 2023 · JNCI Journal of the National Cancer Institute
  2. Application of Microfluidics in Drug Development
    Maryam Parhizkar, Fanjin Wang, Anna Tsitouridou, Dimitrios A. Tsaoulidis · 2024 · AAPS introductions in the pharmaceutical sciences
  3. Challenges in Sustainable Pharmaceutical Development
    Thuy Trang Nguyen, Thi Phuong Trang Nguyen · 2025 · Springer eBooks
  4. Identification of Potential PBP2a Inhibitors Against Methicillin‐Resistant Staphylococcus aureus via Drug Repurposing and Combination Therapy
    Fangfang Jiao, Pinkai Wang, Derong Zeng, Yiqiong Bao, Yan Zhang, Jun Tao, Jingjing Guo · 2025 · Chemical Biology & Drug Design
  5. ИНЖЕНЕРИЯ ТЕРАПЕВТИЧЕСКИХ АНТИТЕЛ: ТЕОРИЯ И ПРАКТИКА#, "Молекулярная биология"
    Ал. А. Луговской · 2017 · Molecular Biology
  6. Engineering Antibodies as Drugs: Principles and Practice
    Alexey A. Lugovskoy · 2017 · Molecular Biology
  7. Active Pharmaceutical Ingredient Cost of Goods: Discovery to Early Development
    Neal G. Anderson, Todd D. Nelson · 2018 · Methods and principles in medicinal chemistry
  8. Gene Patents and the Social Justice Lens
    Colin Farrelly · 2018 · The American Journal of Bioethics
  9. Medicinal Chemical Biology
    Lyn H. Jones · 2021 · Burger's Medicinal Chemistry and Drug Discovery
  10. Synthetic Routes for Venetoclax at Different Stages of Development
    Yi‐Yin Ku, Michael D. Wendt · 2019 · ACS symposium series
  11. Structure-Based Virtual Screening for Differential Inhibition of Aldose Reductase, Implicated in Secondary Complications in Diabetes
    Ranvir Singh · 2021 · Current Research in Diabetes & Obesity Journal
  12. The computationally guided design of selective targeters of multiple proteins (STaMPs) as a new opportunity for small molecule drug discovery
    Thomas M. Kaiser · 2025 · Frontiers in Pharmacology
  13. Clinical trial success rate in lymphoma: fate of trials and agents from 2000 to 2019
    Zhiping Luo, Meng Li, Brian Primeaux et al. · 2025 · Blood Advances
  14. Balancing the extremes for antibody developability: hydrophobic and electrostatic germline framework signatures for CDR-loop compensation
    Vera A. Spanke, Valentin J. Hoerschinger, Clarissa A. Seidler, Katharina B. Kroell, Vincent Wieser, Sabine Imhof-Jung, Benjamin Weiche, Alexander Bujotzek, Guy J. Georges, Klaus Roman Liedl · 2026 · mAbs
  15. Engineering biocompatible polylactic acid (PLA) microcarriers for enhanced 3D cell culture
    Ana Paula Salcedo-Uribe, Ivan Samayoa-Cortes, Natalia Ramirez-Zermeño, Sabrina Navarro-Navarro, Néstor Fabián Díaz, Daniela Ávila‐González, David José Mendoza Aguayo, Nestor Emmanuel Diaz-Martinez · 2026 · Biomedical Microdevices
  16. InChINet: a self-supervised molecular representation learning framework leveraging SMILES and InChI
    Yongna Yuan, Jiahe Kang, Yuanchen Li · 2026 · Physical Chemistry Chemical Physics
  17. Cardiovascular drug development: role of Mendelian randomization
    Jonathan Laurence Ciofani, Anne Tybjærg‐Hansen, Ravinay Bhindi · 2026 · European Heart Journal
  18. H. Steve White: A Champion for Contemporary Epilepsy Research
    Harold Kohn · 2017 · Neurochemical Research
  19. Ophthalmic Start-Up Chief Executive Officers' Perceptions of Development Hurdles
    William C. Stewart, Lindsay A. Nelson, Bonnie Kruft · 2017 · Ophthalmic Research
  20. Target Validation—Prosecuting the Target
    Lyn H. Jones · 2021 · Elsevier eBooks
  21. 3D bioprinting of gastrointestinal cancer models: A comprehensive review on processing, properties, and therapeutic implications
    Kalappa Prashantha, K Amita, Malini Muthappa · 2023 · Biointerphases
  22. Organ-on-chip-based disease models
    Juan M. Fernández‐Costa, Francesco De Chiara, Javier Ramón‐Azcón · 2024 · Elsevier eBooks
  23. Revolutionizing Drug Development: Harnessing Artificial Intelligence in Pharmaceutical Sciences
    Samaresh Pal Roy, Sunil Kumar Kadiri, Suchismita Bhowmik, Vimal Patel, Lokesh Deb, Prashant Kumar Tiwari · 2025 · Current Drug Discovery Technologies
  24. Computers in Clinical Development
    Swati Changdeo Jagdale, Asawaree Anand Hable · 2022 · Springer eBooks
  25. Why some Patients Benefit from Participating in a Sham Surgery Trial
    Ali B. Abbasi, Adam S. Cifu · 2023 · Annals of Surgery
  26. The next frontier in ADME science: Predicting transporter-based drug disposition, tissue concentrations and drug-drug interactions in humans.
    F. Storelli, Mengyue Yin, Aditya R. Kumar, M. K. Ladumor, R. Evers, Paresh P. Chothe, Osatohanmwen J. Enogieru, Xiao-Min Liang, Yu-Rong Lai, J. Unadkat · 2022 · Pharmacology and Therapeutics
  27. Editorial: pharmacokinetic and pharmacodynamic model for vonoprazan—a step forward to precision medicine
    Luigi Gatta · 2023 · Alimentary Pharmacology & Therapeutics
  28. Dynamic Clinical Success Rates for Drugs in the 21st Century
    Ying Zhou, Yintao Zhang, Zhen Chen, Shijie Huang, Yinghong Li, Jianbo Fu, Hongning Zhang, Donghai Zhao, Xichen Lian, Yuan Zhou et al. · 2024 · medRxiv
  29. Dynamic Clinical Success Rates for Drugs in the 21st Century
    Feng Zhu, Ying Zhou, Yintao Zhang, Zhen Chen, Shijie Huang, Yinghong Li, Jianbo Fu, Hongning Zhang, Donghai Zhao, Xichen Lian et al. · 2024 · Research Square
  30. Regulation Flow Analysis discovers molecular mechanisms of action from large knowledge databases
    Carlos P. Roca, Oleg Sysoev, Elena Eyre, Silvia Galan, Dominic Sinibaldi, Philip M. R. Tedder, Jonathan Mangion · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  31. Construction of Enriched Resource for Primary Therapeutic Targets of Approved and Clinical Trial Drugs
    Hong Jun Yang, Chunyan Yu, Yinghong Li, Feng Zhu · 2017 · Journal of Biosciences and Medicines
  32. Relations between Effects and Structure of Small Bicyclic Molecules on the Complex Model System Saccharomyces cerevisiae
    Matteo Brilli, Andrea Trabocchi, Tobias Weil · 2017 · Frontiers in Pharmacology
  33. How to improve success rates of the compounds acting on CNS using biomarkers.
    S. Katsumata · 2017 · Nihon yakurigaku zasshi. Folia pharmacologica Japonica
  34. Flipping the odds of drug development success through human genomics
    Aroon Dinesh Hingorani, Valerie Kuan, Chris Finan, Felix Alexander Krüger, Anna Gaulton, Sandesh Chopade, Reecha Sofat, Raymond J. MacAllister, John P. Overington, Harry Hemingway et al. · 2017 · bioRxiv (Cold Spring Harbor Laboratory)
  35. Informing Decisions in Discovery and Early Development Research Through Quantitative and Translational Modeling
    Tjerk Bueters, Christopher R. Gibson, Prajakti A. Kothare, Mallika Lala, Eric M. Parker, Matthew L. Rizk, Daniel A. Tatosian, Maria E. Trujillo, Pavan K. Vaddady, Sandra A. G. Visser · 2018 · Methods and principles in medicinal chemistry
  36. How do primary/patient-derived cell models compare to mouse models in the study of chronic disease? Do either of these models carry increased translational potential?
    Mitchell J.S. Braam, Timothy J. Kieffer · 2018 · Health Science Inquiry
  37. Chemical Strategies for Evaluating New Drug Targets
    Adrian J. Carter, Raina Seupel, Paul E. Brennan, M. Sundström, Andrea Introini, Anke Mueller‐Fahrnow · 2019 · Methods and principles in medicinal chemistry
  38. Biological and Aetiological Inference from the Statistical Genetic Analyses of Blood Cell Traits
    Parsa Akbari · 2019 · Apollo (University of Cambridge)
  39. Rushed Innovation: Reactive Licensing in the Pharmaceutical Industry
    Manuel Hermosilla · 2019 · SSRN Electronic Journal
  40. Experiences in Academic and Industry Partnerships – Forging a Path to Translational Drug Discovery
    Roland E. Dolle, Denise V. Barrault, Neil O. Carragher, Paul D. Andrews, Daniel V. Ebner, Andrew Hopkins, Hirotatsu Kojima, Stephen V. Frye, Al Edwards, Peter I. Dosa et al. · 2021 · Burger's Medicinal Chemistry and Drug Discovery
  41. Pharmaceutical Camel Products; Marketing Strategies for Successful International Penetration
    Meqbel Mishary Aliedan, Mansour Abdullah Alyahya, Sneha Dhruvakumar · 2021 · Indian Journal of Pharmaceutical Education and Research
  42. Combinations of Drug Candidate Properties Affecting Development Success and Discontinuation for 5 Diseases: Lymphoma, Non–Small Cell Lung Cancer, Arthritis, Depression, and Alzheimer Disease
    Shingo Yamaguchi, Mamoru Narukawa · 2022 · The Journal of Clinical Pharmacology
  43. Faculty Opinions recommendation of Estimation of clinical trial success rates and related parameters.
    David C. Swinney · 2020 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  44. Non-commercial pharmaceutical R&D: what do neglected diseases suggest about costs and efficiency?
    Marcela Vieira, Ryan Kimmitt, Suerie Moon · 2021 · F1000Research
  45. Foreword
    Krishna Kodukula, Kosta Steliou · 2016 · Elsevier eBooks
  46. Clinical Evaluation of New Drugs: From the regulatior’s view point
    文恵 山崎, 中林 哲夫, 克年 猿田 · 2016 · JAPANES JOURNAL OF MEDICAL INSTRUMENTATION
  47. Network medicine approaches to diagnostics and therapeutics
    Asher Ameli · 2020
  48. The importance of drug target selection capability for new drug innovation: definition, fostering process, and interaction with organizational management
    Ryo Okuyama, Masaharu Tsujimoto · 2020 · Prometheus
  49. Beyond Inhibition
    Milka Kostić, Lyn H. Jones · 2022 · Wiley eBooks
  50. Design of Myeloperoxidase Inhibitors as new anti-inflammatory drugs: A in silico, in vitro and in vivo study
    Isaac de Araújo Matos · 2022
  51. Foreword to the first edition
    Krishna Kodukula, Kosta Steliou · 2023 · Elsevier eBooks
  52. Drug Delivery Options for Treatment of Ebola Infection
    Harshita Krishnatreyya, Hemanga Hazarika, Bhrigu Kumar Das, Neelutpal Gogoi, Abdul Baquee Ahmed, Kamaruz Zaman · 2023 · Springer eBooks
  53. Geometric and topological AI for molecular sciences
    JunJie Wee · 2023
  54. Role of Natural Sciences in New Drug Discovery and Integrative Medicine
    Muhammad Nasir Younis · 2023 · Advances in medical diagnosis, treatment, and care (AMDTC) book series
  55. Translational Science
    Outi Vaarala, Sammeli Liikkanen, Anu Moilanen · 2023 · Royal Society of Chemistry eBooks
  56. Organ-on-a-chip systems
    Patrycja Baranowska, Magdalena Flont, Agnieszka Żuchowska, Zbigniew Brzózka, Elżbieta Jastrzębska · 2024 · Elsevier eBooks
  57. Evaluation of a Bayesian hierarchical pharmacokinetic–pharmacodynamic model for predicting parasitological outcomes in Phase 2 studies of new antimalarial drugs
    Meg K. Tully, Saber Dini, Jennifer A. Flegg · 2024 · Antimicrobial Agents and Chemotherapy
  58. Reconsidering Key Theoretical and Policy Issues
    Sun Hl, Madhavi Sunder · 2024 · Cambridge University Press eBooks
  59. Global Medical War Chest
    Lawrence O. Gostin · 2024 · Cambridge University Press eBooks
  60. Measuring the quality of experimental research
    Rafael Ventura · 2025 · Synthese
  61. Calendar Period Estimation of Probabilities of Transition in Drug Development
    Ernesto Schirmacher, Clifton M. Chow, Fred David Ledley · 2025 · medRxiv
  62. Advancing the development of deep learning and machine learning models for oral drugs through diverse descriptor classes: a focus on pharmacokinetic parameters (Vdss and PPB)
    Rakesh Bantu, Samiron Phukan, Simon N. Haydar · 2025 · Molecular Diversity
  63. Profiling Hinge Plasticity in Intact Monoclonal Antibodies for Antigen Recognition
    Arnab Bhattacharya, Shakya Sinha, Rozaleen Dash, Anurag Singh Rathore, Subhabrata Majumder · 2025 · Biochemistry
  64. CNS Drug Discovery in “The Century of Biology”
    Darı́o Doller · 2025
  65. Tumor-on-a-Chip: From Biomimetic Tumor-Immune Microenvironments to Therapeutic Insights
    Yüksel Çetin · 2025 · Biochemistry
  66. Data Privacy Regulation and Innovation
    Jennifer L. Kao, Sukhun Kang · 2026 · SSRN Electronic Journal
  67. Drug repositioning for human MKN45 gastric cancer mouse model using deep learning AI and experimental validation
    Ghazaleh Ghavami, Ramin Ebrahimi Kiasari, Setareh Ghavami · 2026 · European Journal of Pharmacology
  68. Design and preparation of degradable organosilica particles for biomedical applications
    Pierre Picchetti · 2020 · theses.fr (ABES)
  69. Venture Capital Promotes an Increase in Clinical Trials for Medical Enterprises
    Kaihuang Zhang · 2026 · Journal of Pharmaceutical Innovation
  70. VoluAlign-DTA: Enhancing Prediction of Drug-Target Binding Affinity by Integrating Geometric Alignment with Dynamic Multimodal Management
    Mengfan Yuan, Yuan Zhang, Bing Jia · 2026 · Lecture notes in computer science
  71. ERFA: Combining expression data with large knowledge graphs and regulation flow for MoA discovery
    Oleg Sysoev, Carlos P. Roca, Elena Eyre · 2025 · International Conference on Biomedical and Bioinformatics Engineering (ICBBE)
  72. PPAOT predictor: ARKA-RASTR strategy-driven rodent acute oral toxicity prediction for pyrazole and pyrrolidine scaffolds-based chemicals with intelligent mechanistic interpretation
    Jianing Xu, Shuo Chen, Ting Ren · 2026 · Archives of Toxicology
  73. Marine discovery, nonmarine deployment: A translation paradox in blue biotechnology
    Marco F.L. Lemos · 2026 · Trends in biotechnology
  74. Machine Learning in Ligand-based Drug Design
    Nikita Krishna, Mohammad Imran Siddiqi · 2026 · Royal Society of Chemistry eBooks
  75. Mapping the Global Technology Landscape and Dynamic Evolution of Artificial Intelligence-assisted Drug R&D Based on Patent Analysis
    Jiajia Wen, Xiang Mei Yu, Wei Yang · 2026 · Journal of Pharmaceutical Innovation
  76. Flow-dependent drug response of breast Cancer organoids in an organ-on-Chip platform
    Ece Kocamaz, Deren Aslan, Veli Özbolat, Tolga Köşeci, Çetin Canpolat · 2026 · Microchemical Journal
  77. APPLICATION OF MACHINE LEARNING METHODS IN EARLY DRUG DEVELOPMENT
    A. S. Maksimov, Ж. М. Дергачёва · 2026 · Vestnik Farmacii
  78. Data-centric feedback loops for next-generation immunotherapy development
    Rotem Shalita, Ido Amit · 2026 · Nature Biomedical Engineering